Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Good news for peptide-prescribers and patients. The FDA is removing some fan favorites from the Category 2 bulk substances list, including.... AOD-9604 BPC-157 CJC-1295 Ipamorelin Thymosin a1 Selank Happy Saturday to us! 🥳
Column: A federal appeals court hands the FDA a stupendous win in its battle against stem cell clinics https://t.co/enLmOk4xZ8
Great news (I think): 9th Cir affirms FDA power to regulate adipose cell therapies as drugs: see @pknoepfler at https://t.co/fUeR1x9q7r Here, from his post, is a link to the decision: https://t.co/g6JPrYzklb Oddly split court; unan on 4 parts, 2 w/1 concurring in result on 3rd
The U.S. Food and Drug Administration (FDA) secured a significant victory in a federal appeals court, which affirmed the agency's authority to regulate stem cell clinics. The 9th Circuit Court of Appeals ruled in favor of the FDA, allowing it to classify adipose cell therapies as drugs. This decision, which was unanimous on four parts, reinforces the FDA's regulatory power over stem cell treatments, a closely watched issue in the medical community.
